Cerezyme (Imiglucerase) - Summary

CEREZYME SUMMARY

(Logo) Cerezyme^®
(imiglucerase for injection)

Cerezyme ^® (imiglucerase for injection) is an analogue of the human enzyme (beta)-glucocerebrosidase, produced by recombinant DNA technology. (beta)-Glucocerebrosidase ((beta)-D-glucosyl-N-acylsphingosine glucohydrolase, E.C. 3.2.1.45) is a lysosomal glycoprotein enzyme which catalyzes the hydrolysis of the glycolipid glucocerebroside to glucose and ceramide.

Cerezyme ^® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

1. anemia
2. thrombocytopenia
3. bone disease
4. hepatomegaly or splenomegaly

CEREZYME NEWS HIGHLIGHTS

Media Articles Related to Cerezyme (Imiglucerase)

imiglucerase-injection, Cerezyme
Source: MedicineNet Gaucher Disease Specialty [2005.03.02]

more>>

Published Studies Related to Cerezyme (Imiglucerase)

Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. [2007.02]

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. [2008.05]

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. [2008.02.27]

Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase. [2008.01.23]

Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination. [2007.07]

more>>

Clinical Trials Related to Cerezyme (Imiglucerase)

Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease [Completed]

A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease. [Completed]

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease [Recruiting]

Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase [Not yet recruiting]

Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase [Recruiting]

more>>